MED logo

Medifast, Inc. Stock Price

NYSE:MED Community·US$129.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 25 Fair Values set on narratives written by author

MED Share Price Performance

US$12.59
12.59 (0.00%)
US$12.00
Fair Value
US$12.59
12.59 (0.00%)
4.9% overvalued intrinsic discount
US$12.00
Fair Value
Price US$12.59
AnalystConsensusTarget US$12.00

MED Community Narratives

·
Fair Value US$12 4.9% overvalued intrinsic discount

Digital Health And GLP-1 Focus Will Offer Opportunities Despite Risks

2users have liked this narrative
0users have commented on this narrative
13users have followed this narrative

Trending Discussion

Updated Narratives

MED logo

MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook

Fair Value: US$12 4.9% overvalued intrinsic discount
13 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

0 Risks
0 Rewards

Medifast, Inc. Key Details

US$346.1m

Revenue

US$103.4m

Cost of Revenue

US$242.7m

Gross Profit

US$262.7m

Other Expenses

-US$20.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-1.95
70.12%
-5.79%
0%
View Full Analysis

About MED

Founded
1980
Employees
380
CEO
Daniel Chard
WebsiteView website
medifastinc.com

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients’ long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss without the stress of figuring out what to eat. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.

Recent MED News & Updates

Narrative Update May 19

MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook

Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.
Seeking Alpha May 12

Medifast: Worth Putting On A Watchlist

Summary Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.5 if MED's earnings stabilize over the mid-term. Such upside is speculative, though. Read the full article on Seeking Alpha

Recent updates

No updates